Published in Leuk Lymphoma on April 23, 2012
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf (2012) 0.94
Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget (2013) 0.82
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmgenomics Pers Med (2014) 0.82
Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol (2016) 0.79
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf (2016) 0.78
Brentuximab Vedotin in CD30+ Lymphomas. Biol Ther (2013) 0.77
Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma. Radiol Oncol (2015) 0.75
A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin. Chin J Cancer (2013) 0.75
Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. Br J Radiol (2016) 0.75
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med (2014) 3.86
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol (2002) 2.25
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med (2005) 1.85
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.82
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood (2013) 1.72
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res (2011) 1.67
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood (2003) 1.66
Delayed fingolimod-associated asystole. Mult Scler (2011) 1.61
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol (2009) 1.61
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol (2013) 1.59
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol (2007) 1.52
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood (2012) 1.49
18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med (2011) 1.45
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma (2011) 1.44
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol (2009) 1.44
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood (2011) 1.44
High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. J Clin Microbiol (2006) 1.34
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol (2012) 1.28
Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol (2004) 1.27
The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci (2007) 1.23
Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol (2015) 1.21
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood (2002) 1.20
Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol (2012) 1.17
Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol (2004) 1.15
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood (2012) 1.15
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer (2011) 1.14
ALS syndrome in patients with HIV-1 infection. J Neurol Sci (2005) 1.14
Stroke in HIV infection and AIDS. Expert Rev Cardiovasc Ther (2009) 1.09
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma (2007) 1.08
Update on progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep (2012) 1.06
Mass lesions of the brain in AIDS: the dilemmas of distinguishing toxoplasmosis from primary CNS lymphoma. AJNR Am J Neuroradiol (2003) 1.02
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol (2014) 1.00
Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw (2015) 1.00
Therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 0.98
Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J (2012) 0.96
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant (2014) 0.95
Isolated Histoplasma capsulatum meningoencephalitis in an immunocompetent child. J Child Neurol (2012) 0.94
Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci (2002) 0.94
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol (2009) 0.93
The bone marrow, B cells, and JC virus. J Neurovirol (2008) 0.93
Anti-CD30 Antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep (2010) 0.93
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol (2010) 0.93
Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy (2011) 0.93
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol (2013) 0.91
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol (2013) 0.91
Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J Nucl Med (2013) 0.90
Steroids for PML-IRIS: a double-edged sword? Neurology (2009) 0.89
Salvage regimens for Hodgkin lymphoma. Clin Adv Hematol Oncol (2008) 0.89
Blinatumomab for the treatment of B-cell lymphoma. Expert Opin Investig Drugs (2015) 0.88
Central Nervous System Infections With Immunomodulatory Therapies. Continuum (Minneap Minn) (2015) 0.87
Low prevalence of varicella zoster virus and herpes simplex virus type 2 in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.87
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma (2014) 0.87
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids following influenza vaccination. Arch Pathol Lab Med (2012) 0.86
The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol (2011) 0.86
Wernicke's encephalopathy in the course of chemoradiotherapy for head and neck cancer. Am J Otolaryngol (2010) 0.86
A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol (2006) 0.86
Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer (2014) 0.85
Complications of immunosuppressive/immunomodulatory therapy in neurological diseases. Curr Treat Options Neurol (2012) 0.85
Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep (2013) 0.85
Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy (2006) 0.85
Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer (2014) 0.84
Monofocal acute inflammatory Demyelination (MAID): a unique disorder simulating brain neoplasm. South Med J (2002) 0.84
Role of routine imaging in lymphoma. J Natl Compr Canc Netw (2011) 0.84
JCV-specific CD4 T cell response: another piece of the puzzle in explaining some aspects of AIDS associated PML. AIDS (2003) 0.83
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. Cancer (2002) 0.83
Therapy of relapsed Hodgkin lymphoma. Blood Rev (2007) 0.83
Progressive Multifocal Leukoencephalopathy: Recent Advances and a Neuro-Ophthalmological Review. J Neuroophthalmol (2015) 0.83
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol (2014) 0.82
Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary. J Clin Oncol (2013) 0.81
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist (2012) 0.81
Alien hand syndrome. Neurology (2006) 0.81
Substantia nigra depigmentation and exposure to encephalitis lethargica. Ann Neurol (2012) 0.81
Spinal epidural abscess. Curr Infect Dis Rep (2014) 0.81
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma (2013) 0.81
Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs (2015) 0.81
Drug development for recurrent and refractory classical Hodgkin lymphoma. Leuk Lymphoma (2009) 0.81
Disease-modifying drugs for multiple sclerosis and JC virus expression. J Neurovirol (2012) 0.79
Cervical myelopathy secondary to violent tics of Tourette's syndrome. Neurology (2003) 0.79
Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma? Curr Hematol Malig Rep (2012) 0.79
Introduction to HIV infection and neuro-AIDS. Handb Clin Neurol (2007) 0.79
The manifold faces of PML and the challenge of diagnosis. Neurology (2011) 0.79
The changing landscape of progressive multifocal leukoencephalopathy. Curr Infect Dis Rep (2011) 0.79
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma (2014) 0.79
Reply to "'Thinking without thinking' about natalizumab and PML". J Neurol Sci (2007) 0.78
An international screening tool for HIV dementia. AIDS (2005) 0.78
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol (2008) 0.78